[1] | A. Alzheimer; “Über eine eigenartige Erkrankung der Hirnrinde”, Allgemeine Zeitschrift fur Psychiatrie und Psychisch-Gerichtlich Medizin, 1907, 64(1–2), 146-148. |
[2] | N.C. Berchtold, C.W. Cotman; "Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s", Neurobiology of Aging, 1998, 19(3), 173–189. [DOI: 10.1016/s0197-4580(98)00052-9]. |
[3] | U. Maurer, K. Maurer; “Alzheimer: The Life of a Physician and the Career of a Disease” New York: Columbia University Press. 2003, p. 270. (ISBN: 978-0-231-11896-5). |
[4] | “Alzheimer's Disease Fact Sheet"; National Institute on Aging, 2021. https://www.nia.nih.gov/health/alzheimers-disease-fact-sheet. |
[5] | “Dementia: A public health priority” Alzheimer's Disease International, World Health Organization, 2012, 1-102. (ISBN: 978-92-4-156445-8). |
[6] | Basics of Alzheimer's disease and dementia, National Institute on Aging. https://www.nia.nih.gov/health/alzheimers/basics. |
[7] | H.W. Querfurth, F.M. LaFerla; "Alzheimer's Disease", The New England Journal of Medicine. 2010, 362(4), 329-344. [DOI: 10.1056/NEJMra0909142] |
[8] | Z. Breijyeh, R. Karaman; “Comprehensive review on Alzheimer's disease: Causes and treatment”, Molecules, 2020, 25(24), 5789(1-28). [DOI: 10.3390/molecules25245789] |
[9] | J. Gaugler, B. James, T. Johnson, J. Reimer, M. Solis, J. Weuve, R.F. Buckley, T.J. Hohman, Special Report, “Special Report: More Than Normal Aging: Understanding Mild Cognitive Impairment; 2022 Alzheimer’s Disease Facts and Figures”, Alzheimer's Association Report, Alzheimer's & Dementia: The Journal of The Alzheimer's Association, 2022, 18(4), 1-118 or 700-789 (ISSN:1552-5260, eISSN:1552-5279). [DOI: 10.1002/alz.12638]. |
[10] | M. De Jesus, M. Moreno; “Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: A multicenter, double-blind, randomized, placebo-controlled trial”, Clinical Therapeutics, 2003, 25(1), 178-193. [DOI: 10.1016/S0149-2918(03)90023-3] |
[11] | L. Parnetti, F. Mignini, D. Tomassoni, E. Traini, F. Amenta; “Cholinergic precursors in the treatment of cognitive impairment of vascular origin: Ineffective approaches or need for re-evaluation?”, Journal of the Neurological Sciences, 2007, 257(1–2), 264-269. [DOI: 10.1016/j.jns.2007.01.043] |
[12] | P.T. Francis, A.M. Palmer, M. Snape, G.K. Wilcock; 1999, 66(2), 137-147. [DOI: 10.1136/jnnp.66.2.137]; T. Babic; 1999, 67(4), 558. [DOI: 10.1136/jnnp.67.4.558]. “The cholinergic hypothesis of Alzheimer's disease: A review of progress”, Journal of Neurology, Neurosurgery, and Psychiatry. |
[13] | M.C. Falk; “Generally Recognized as safe (GRAS): Determination for the Use of Alpha Size® Alpha-Glycerylphosphoryl Choline”, Life Sciences Research Organization, Inc., US Food and Drug Administration, 2012, 1-136. (GRAS Notice: GRN 419) https://www.fda.gov/food/food-ingredients-packaging/generally-recognized-safe-gras. |
[14] | A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, D. Forman; “Global Cancer statistics”, CA: a Cancer Journal for Clinicians, 2011, 61(2), 69-90. [DOI: 10.3322/caac.20107]. |
[15] | “Cancer Fact Sheet”; International Agency for Research on Cancer, World Health Organization, 2020. https://gco.iarc.fr/today/fact-sheets-cancers. |
[16] | “National Cancer Institute (NCI)”; National Institutes of Health, U.S. Department of Health and Human Services, 2022. https://www.nih.gov/about-nih/what-we-do/nih-almanac/national-cancer-institute-nci. |
[17] | “Suspected cancer: recognition and referral, (NG12)”; National Institutes for Health and Care Excellence, published: 2015, updated: 2021, 1-98. |
[18] | C.P. Wild, E. Weiderpass, B.W. Stewart; “World Cancer Report: Cancer Research for Cancer Prevention”, International Agency for Research on Cancer, World Health Organization, 2020. (ISBN: 978-92-832-0447-3, 978-92-832-0448-0). |
[19] | C.J.L. Murray, A.D. Lopez, T. Vos (Disease and Injury Incidence and Prevalence Collaborators); “Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015”, The Lancet, 2016, 388(10053), 1545-1602. [DOI: 10.1016/S0140-6736(16)31678-6] |
[20] | M. Sciacovelli, C. Schmidt, E.R. Maher, C. Frezza; “Metabolic Drivers in Hereditary Cancer Syndromes”, Annual Review of Cancer Biology, Annual Reviews, 2020, 4, 77-97. [DOI: 10.1146/annurev-cancerbio-030419-033612] |
[21] | Global burden of disease study 2019 Cancer collaboration: J.M. Kocarnik; et. al.; “Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 Cancer groups from 2010 to 2019: A systematic analysis for the global burden of disease study 2019”, JAMA Oncology. 2022, 8(3), 420-444. [DOI: 10.1001/jamaoncol.2021.6987] |
[22] | R. Pazdur, L.D. Wagman, K.A. Camphausen, W.J. Hoskins; “Cancer Management: A Multidisciplinary Approach” 12th edition, Cmp Healthcare Media, 2009, 1-1050. (ISBN: 978-1-891483-63-9). |
[23] | E. Thomas, M. Yoneda, E.R. Schiff; “Viral Hepatitis: Past and Future of HBV and HDV”, Cold Spring Harbor Perspective Medicine, 2015, 5(2), 1-11. [DOI: 10.1101/cshperspect.a021345] |
[24] | G.S. Burns, A.J. Thompson; “Viral Hepatitis B: Clinical and Epidemiological Characteristics”, Cold Spring Harbor Perspective Medicine, 2014, 4(12), 1-14. [DOI: 10.1101/cshperspect.a024935] |
[25] | W. Bernal, J. Wendon; “Critical care medicine: Acute liver failure”, The New England Journal of Medicine 2013, 369(26), 2525-2534. [DOI: 10.1056/NEJMra1208937] |
[26] | Part 10, Section 3, Chapters 329-338; “Liver and Biliary Tract Disease”, in J.L. Jameson, A.S. Fauci, D.L. Kasper, S.L. Hauser, D.L. Longo, J. Loscalzo; Harrison's Principles of Internal Medicine, 20th Edition. New York, NY: McGraw-Hill Education Medical; 2018. (ISBN: 978-1-25-964403-0). |
[27] | Part IX, Chapters 38-40, Pages 1003-1052; “Infectious and Granulomatous Disease”. in E.R. Schiff, W.C. Maddrey, K.R. Reddy; Schiff’s Diseases of the Liver, 12th Edition, John Wiley & Sons Ltd. 2017, 1-1213. (ISBN: 978-1-11-925122-4, 978-1-11-925131-6). [DOI: 10.1002/9781119251316] |
[28] | Part III, Chapters 10-19, Pages 269-487; “Consequences of Liver Disease” in E.R. Schiff, W.C. Maddrey, K.R. Reddy; Schiff’s Diseases of the Liver, 12th Edition, John Wiley & Sons Ltd. 2017, 1-1213. (ISBN: 978-1-11-925122-4, 978-1-11-925131-6). [DOI: 10.1002/9781119251316] |
[29] | R.B. Pinto, A.C.R. Schneider, T.R. da Silveira; “Cirrhosis in children and adolescents: An overview”, 2015, 7(3), 392-405. [DOI: 10.4254/wjh.v7.i3.392] |
[30] | E.Y. Cheng, A. Zarrinpar, D.A. Geller, J.A. Goss, R.W. Busuttil; Chapter 31, Pages 1263-1308; “Liver"; in F.C. Brunicardi, D.K. Anderson, T.R. Billiar, D.L. Dunn, J.G. Hunter, J.B. Matthews, R.E. Pollock; Schwartz's principles of surgery, 10th Edition, New York: McGraw-Hill Education Medical, 2015, 1-2098. (ISBN: 978-0-07-180092-1, 978-0-07-179675-0). |
[31] | “Viral Hepatitis”, Centers for Disease Control and Prevention, 2021. https://www.cdc.gov/hepatitis/hbv/index.htm. |
[32] | C.K. Fairley, T.R.H. Read; “Vaccination against sexually transmitted infections”, Current Opinion in Infectious Diseases, 2012, 25(1), 66-72. [DOI: 10.1097/QCO.0b013e32834e9aeb] |
[33] | F. Buddeberg, B.B. Schimmer, D.R. Spahn; “Transfusion-transmissible infections and transfusion-related immunomodulation”, Best Practice & Research in Clinical Anaesthesiology, 2008, 22(3), 503-517. [DOI: 10.1016/j.bpa.2008.05.003] |
[34] | R.A. Hughes; “Drug Injectors and the Cleaning of Needles and Syringes” Special Topic Section: Development of Harm Reduction and Methadone Maintenance in Europe, European Addiction Research, 2000, 6(1), 20-30. [DOI: 10.1159/000019005] |
[35] | H. Yan, G. Zhong, G. Xu, W. He, Z. Jing, Z. Gao, Y. Huang, Y. Qi, B. Peng, H. Wang, L. Fu, M. Song, P. Chen, W. Gao, B. Ren, Y. Sun, T. Cai, X. Feng, J. Sui, W. Li; “Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus”, Biochemistry | Microbiology and Infectious Diseases, eLIFE, 2012, 1:e00049, 1-28. [DOI: 10.7554/eLife.00049.001] |
[36] | A. Vittal, M.G. Ghany; “WHO Guidelines for Prevention, Care and Treatment of Individuals Infected with HBV: A US Perspective”. Clinics in Liver Disease, 2019, 23(3), 417-432. [DOI: 10.1016/j.cld.2019.04.008] |
[37] | P. Marcellin, T.T. Chang, S.G. Lim, M.J. Tong, W. Sievert, M.L. Shiffman, L. Jeffers, Z. Goodman, M.S. Wulfsohn, S. Xiong, J. Fry, C.L Brosgart, Adefovir Dipivoxil 437 Study Group; “Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B”, The New England Journal of Medicine, 2003, 348(9), 808-816. [DOI: 10.1056/NEJMoa020681] |
[38] | S. Manolakopoulos, S. Bethanis, S. Koutsounas, J. Goulis, J. Vlachogiannakos, E. Christias, A. Saveriadis, C. Pavlidis, C. Triantos, A. christidou, G. Papatheodoridis, D. Karamanolis, D. Tzourmakliotis; “Long-term therapy with Adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to Lamivudine”, Alimentary Pharmacology & Therapeutics, 2007, 27(3), 266-273. [DOI: 10.1111/j.1365-2036.2007.03567.x] |
[39] | P. Reiss, “A randomized placebo-controlled trial of Adefovir dipivoxil in advanced HIV infection: the ADHOC trial”, ADHOC International Steering Committee; HIV Medicine, 2002, 3(4), 229-238. |
[40] | D. Thaczuk, S.R. Hosein, B. Ziegler; "3TC (lamivudine, Epivir)", CATIE. 2014. |
[41] | G.W. Koszalka, S.M. Daluge, F.L. Boyd; “Chapter 16-Advances in Nucieoside and Nucleotide Antiviral Therapies”, Annual Reports in Medicinal Chemistry, 1998, 30, 163-171. [DOI: 10.1016/S0065-7743(08)61081-7] |
[42] | J. Fischer, C.R. Ganellin, C.R.; “Lamivudine”, Analogue-based Drug Discovery, John Wiley-VCH Verlag GmbH & Co. KGaA, 2006, 506. (ISBN: 978-3-52-731257-3, 978-3-52-760800-3). [DOI: 10.1002/3527608001] |
[43] | “Global HIV & AIDS Statistics-Fact Sheet”. UNAIDS, 2022. https://www.unaids.org/en/resources/fact-sheet |
[44] | “Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV”. US Department of Health and Human Services, 2021, 1-454. |
[45] | I. Molotsky; “US Approves Drug to Prolong Lives of AIDS Patience”. New York Times, 1987-03-21. |
[46] | P. Emau, Y. Jiang, M.B. Agy, B. Tian, G. Bekele, C-C. Tsai; “Post-exposure prophylaxis for SIV revisited: Animal model for HIV prevention”, AIDS Research and Therapy, 2006, 3(29), 1-14. [DOI: 10.1186/1742-6405-3-29] |
[47] | Gilead Sciences, Inc. “Prescribing Information: DESCOVY® (Emtricitabine and Tenofovir, Alafenamide) tablets, for oral use”, Initial U.S. Approval: 2015, Revised: 2016, 1-28. (Reference ID: 3911541) [©2016 Gilead Sciences, Inc. All rights reserved. GILP0636 04/16 and 208215-GS-000] |
[48] | B.P. Kearney, J.F. Flaherty, J. Shah; “Tenofovir disoproxil fumarate: Clinical pharmacology and pharmacokinetics”, Clinical Pharmacokinetics, 2004, 43(9), 595-612. [DOI: 10.2165/00003088-200443090-00003] |
[49] | Gilead Sciences Inc. “VIREAD, (Tenofovir disoproxil fumarate) tablets/powder, for oral use”, Initial U.S. Approval: 2001, Revised: 2019, 1-49. [©2019 Gilead Sciences, Inc. All rights reserved. 21356-GS-041 and 21356-GS-022 240908] |
[50] | V. Agrahari, S.M. Anderson, M.M. Peet, A.P. Wong, O.N. Singh, G.F. Doncel, M.R. Clark; “Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges”, Expert Opinion on Drug Delivery, 2022, 19(10), 1365-1380. [DOI: 10.1080/17425247.2022.2135699] |
[51] | L.C. Rohan, A.B. Sassi; “Vaginal drug delivery systems for HIV prevention”, The AAPS Journal, 2009, 11(1), 78-87. [DOI: 10.1208/s12248-009-9082-7] |
[52] | V.M.K. Ndesendo, V. Pillay, Y.E. Choonara, E. Buchmann, D.N. Bayever, L.C.R. Meyer; “A review of current intra-vaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections”, AAPS Pharm. Sci. Tech. 2008, 9(2), 505-520. [DOI: 10.1208/s12249-008-9073-5] |
[53] | J. das Neves, J. Michiels, K.K. Arien, G. Vanham, M. Amiji, M.F. Bahia, B. Sarmento; “Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate Dapivirine”, Pharmaceutical Research, 2011, 2012, 1468-1484. [DOI: 10.1007/s11095-011-0622-3] |
[54] | F.X. Mbopi-Keou, S. Trottier, R.F. Omar, N.N. Nkele, S. Fokoua, E.R. Mbu, M.C. Domingo, J.F. Giguere, J. Piret, A. Mwatha, B. Masse, M.G. Bergeron; “A randomized, double-blind, placebo-controlled Phase-II extended safety study of two invisible condom formulations in Cameroonian women”, Contraception, 2010, 81(1), 79-85. [DOI: 10.1016/j.contraception.2009.07.002] |
[55] | S. McCormack, G. Ramjee, A. Kamali, H. Rees, A.M. Crook, M. Gafos, U. Jentsch, R. Pool, M. Chisembele, S. Kapiga, R. Mutemwa, A. Vallely, T. Palanee, Y. Sookrajh, C.J. Lacey, J. Darbyshire, H. Grosskurth, A. Profy, A. Nunn, R. Hayes, J. Weber; “PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): A phase 3, randomised, double-blind, parallel-group trial”, Lancet, 2010, 376(9749), 1329-1337. [DOI: 10.1016/S0140-6736(10)61086-0] |
[56] | L. Wan, S. Pooyan, P. Hu, M.J. Leibowitz, S. Stein, P.J. Sinko; “Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage-targeted PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarriers for improving HIV drug delivery”, Pharmaceutical Research, 2007, 24(11), 2110-2119. [DOI: 10.1007/s11095-007-9402-5] |
[57] | M.M. Peet, V. Agrahari, S.M. Anderson, H. Hanif, O.N. Singh, A.R. Thurman, G.F. Doncel, M.R. Clark; “Topical inserts: A versatile delivery form for HIV prevention”, Pharmaceutics, 2019, 11(8), 374(1-17). [DOI: 10.3390/pharmaceutics11080374] |
[58] | Q. Abdool Karim, S.S. Abdool Karim, J.A. Frohlich, A.C. Grobler, C. Baxter, L.E. Mansoor, A.B. Kharsany, S. Sibeko, K.P. Mlisana, Z. Omar, T.N. Gengiah, S. Maarschalk, N. Arulappan, M. Mlotshwa, L. Morris, D. Taylor; “Effectiveness and safety of Tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women”, Science. 2010, 329(5996), 1168-1174. [DOI: 10.1126/science.1193748] |
[59] | L.C. Rohan, B.J. Moncla, N. Kunjara, R.P. Ayudhya, M. Cost, Y. Huang, F. Gai, N. Billitto, J.D. Lynam, K. Pryke, P. Graebing, N. Hopkins, J.F. Rooney, D. Friend, C.S. Dezzutti; “In vitro and ex vivo testing of Tenofovir shows it is effective as an HIV-1 microbicide”, PLoS One. 2010, 5(2), e9310. [DOI: 10.1371/journal.pone.0009310] |
[60] | D. Alukda, T. Sturgis, B.-B.C. Youan; “Formulation of Tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention”, Journal of Pharmaceutical Sciences, 2011, 100(8), 3345-3356. [DOI: 10.1002/jps.22529] |
[61] | K.H. Mayer, L.A. Maslankowski, F. Gai, W.M. El-Sadr, J. Justman, A. Kwiecien; B. Masse, S.H. Eshleman, C. Hendrix, K. Morrow, J.F. Rooney, L. Soto-Torres, HPTN Protocol Team; “Safety and tolerability of Tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women”, AIDS. 2006, 20(4), 543-551. [DOI: 10.1097/01.aids.0000210608.70762.c3] |
[62] | R.K. Rosen, K.M. Morrow, A. Carballo-Dieguez, J.E. Mantell, S. Hoffman, F. Gai, L. Maslankowski, W.M. El-Sadr, K.H. Mayer; “Acceptability of Tenofovir gel as a vaginal microbicide among women in a phase-I trial: A mixed-methods study”, Journal of Womens Health (Larchmt). 2008, 17(3), 383-392. [DOI: 10.1089/jwh.2006.0325] |
[63] | B.B. Saxena, Y.A. Han, D. Fu, P. Rathnam, M. Singh, J. Laurence, S. Lerner; “Sustained release of microbicides by newly engineered vaginal rings”, AIDS. 2009, 23(8), 917-922. [DOI: 10.1097/QAD.0b013e32832af57c] |
[64] | K.M. Gupta, S.R. Barnes, R.A. Tangaro, M.C. Roberts, D.H. Owen, D.F. Katz, P.F. Kiser; “Temperature and pH sensitive hydrogels: An approach towards smart semen-triggered vaginal microbicidal vehicles”, Journal of Pharmaceutical Sciences, 2007, 96(3), 670-681. [DOI: 10.1002/jps.20752] |
[65] | A. Mahalingam, J.I. Jay, K. Langheinrich, S. Shukair, M.D. McRaven, L.C. Rohan; B.C. Herold, T.J. Hope, P.F. Kiser; “Inhibition of the transport of HIV in vitro using a pH- 169 responsive synthetic mucin-like polymer system”, Biomaterials. 2011, 32(33), 8343-8355. [DOI: 10.1016/j.biomaterials.2011.05.001] |
[66] | M.R. Clark, H.A. Aliyar, C.W. Lee, J.I. Jay, K.M. Gupta, K.M. Watson, R.J. Stewart, R.W. Buckheit, P.F. Kiser; “Enzymatic triggered release of an HIV-1 entry inhibitor from prostate specific antigen degradable microparticles”, International Journal of Pharmaceutics, 2011, 413(1-2), 10-18. [DOI: 10.1016/j.ijpharm.2011.04.004] |
[67] | T. Zhang, T.F. Sturgis, B.-B.C. Youan; “pH-responsive nanoparticles releasing Tenofovir intended for the prevention of HIV transmission”, European Journal of Pharmaceutics and Biopharmaceutics, 2011, 79(3), 526-536. [DOI: 10.1016/j.ejpb.2011.06.007] |
[68] | F. Cilurzo, F. Selmin, P. Minghetti, I. Rimoldi, F. Demartin, L. Montanari; “Fast-dissolving mucoadhesive microparticulate delivery system containing Piroxicam”, European Journal of Pharmaceutical Sciences, 2005, 24(4), 355-361. [DOI: 10.1016/j.ejps.2004.11.010] |
[69] | T. Zhang, C. Zhang, V. Agrahari, J.B. Murowchick, N.A. Oyler, B.-B.C. Youan; “Spray drying tenofovir loaded mucoadhesive and pH-sensitive microspheres intended for HIV prevention”, Antiviral Research, 2013, 97(3), 334-346. [DOI: 10.1016/j.antiviral.2012.12.019] |
[70] | D. Nevozhay, U. Kañska, R. Budzyñska, J. Boratyñski; “Współczesny stan badań nad koniugatami i innymi systemami dostarczania leków w leczeniu schorzeń nowotworowych i innych jednostek chorobowych”, Translated: “Current status of research on conjugates and related drug delivery systems in the treatment of cancer and other diseases”, Postepy Higieny i Medycyny Doswiadczalnej, 2007, 61, 350-360. [PMID: 17554238] |
[71] | S.S. Suri, H. Fenniri, B. Singh; “Nanotechnology-based drug delivery systems”, Journal of Occupational Medicine and Toxicology, 2007, 2, 16(1-6). [DOI: 10.1186/1745-6673-2-16] |
[72] | I. Brigger, C. Dubernet, P. Couvreur; “Nanoparticles in cancer therapy and diagnosis”, Advanced Drug Delivery Reviews, 2002, 54(5), 631-651. [DOI: 10.1016/s0169-409x(02)00044-3] |
[73] | S. Marchesan, M. Prato; “Nanomaterials for (Nano) medicine”, ACS Medicinal Chemistry Letters, 2013, 4(2), 147-149. [DOI: 10.1021/ml3003742] |
[74] | P.A. McCarron, M. Hall; “Pharmaceutical Nanotechnology”, Encyclopedia of Nanoscience and Nanotechnology, 2004, 8, 469-487. (ISBN: 1-58883-064-0) |
[75] | L. Mei, Z. Zhang, L. Zhao, L. Huang, X.-L. Yang, J. Tang, S.-S. Feng; “Pharmaceutical nanotechnology for oral delivery of anticancer drugs”, Advanced Drug Delivery Reviews, 2013, 65(6), 880-890. [DOI: 10.1016/j.addr.2012.11.005] |
[76] | T. Musacchio, V.P. Torchilin; “Recent developments in lipid-based pharmaceutical nanocarriers”, Frontiers in Bioscience Landmark, 2011, 16, 1388-1412. [DOI: 10.2741/3795] |
[77] | L. Zhang, F.X. Gu, J.M. Chan, A.Z. Wang, R.S. Langer, O.C. Farokhzad; “Nanoparticles in Medicine: Therapeutic Applications and Developments”, Clinical Pharmacology and Therapeutics, 2008, 83(5), 761-769. [DOI: 10.1038/sj.clpt.6100400] |
[78] | N. Nagai, H. Otake; “Novel drug delivery systems for the management of dry eye”, Advanced Drug Delivery Reviews, 2022, 191, 114582(1-16). [DOI: 10.1016/j.addr.2022.114582] |
[79] | H.J. Smith, H. Williams “Smith and Williams’ Introduction to the Principles of Drug Design and Action”, 4th edition. (ISBN: 978-1-03-230661-2). |
[80] | I. Henriksen, S.A. Sande, G. Smistad, T. Agren, J. Karlsen; “In vitro evaluation of drug release kinetics from liposomes by fractional dialysis”, International Journal of Pharmaceutics, 1995, 119(2), 231-238. [DOI: 10.1016/0378-5173(94)00403-R] |
[81] | S.J. Wallace, J. Li, R.L. Nation, B.J. Boyd; “Drug release from nanomedicines: selection of appropriate encapsulation and release methodology”, Drug Delivery and Translational Research, 2012, 2, 284-292. [DOI: 10.1007/s13346-012-0064-4] |
[82] | M.Y. Levy, S. Benita; “Drug release from submicronized o/w emulsion: a new in vitro kinetic evaluation model”, International Journal of Pharmaceutics, 1990, 66(1-3), 29-37. [DOI: 10.1016/0378-5173(90)90381-D] |
[83] | G. Moreno-Bautista, K.C. Tam; “Evaluation of dialysis membrane process for quantifying the in vitro drug-release from colloidal drug carriers”, Colloids and Surfaces A: Physiochemical and Engineering Aspects; 2011, 389(1-3), 299-303. [DOI: 10.1016/j.colsurfa.2011.07.032] |
[84] | D. Friedman, S. Benita; “A mathematical model for drug release from o/w emulsions: Application to controlled release Morphine emulsions”, Drug Development and Industrial Pharmacy, 1987, 13(9-11), 2067-2085. [DOI: 10.3109/03639048709068707] |
[85] | C. Washington; “Evaluation of non-sink dialysis methods for the measurement of drug release from colloids: effects of drug partition”, International Journal of Pharmaceutics, 1989, 56, 71-74. [DOI: 10.1016/0378-5173(89)90062-8] |
[86] | C. Washington; “Drug release from microdisperse systems: a critical review”, International Journal of Pharmaceutics, 1990, 58, 1-12. [DOI: 10.1016/0378-5173(90)90280-H] |
[87] | P. Calvo, J.L. Vila-Jato, M.J. Alonso; “Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers”, Journal of Pharmaceutical Sciences, 1996. 85(5), 530-536. [DOI: 10.1021/js950474+] |
[88] | X. Xu, M.A. Khan, D.J. Burgess; “A two-stage reverse dialysis in vitro dissolution testing method for passive targeted liposomes”, International Journal of Pharmaceutics, 2012, 426(1–2), 211-218. [DOI: 10.1016/j.ijpharm.2012.01.030] |
[89] | V. Agrahari, B-B.C. Youan; “Sensitive and Rapid HPLC Quantification of Tenofovir from Hyaluronic Acid-Based Nanomedicine”, AAPS. Pharm. Sci. Tech. 2012, 13(1), 202-210. [DOI: 10.1208/s12249-011-9735-6] |
[90] | S. Sentenac, C. Fernandez, A. Thuillier, P. Lechat, G. Aymard; “Sensitive determination of Tenofovir in human plasma samples using reversed-phase liquid chromatography”, Journal of Chromatography B, 2003, 793(2), 317-324. [DOI: 10.1016/s1570-0232(03)00333-7] |
[91] | M. Takahashi, Y. Kudaka, N. Okumura, A. Hirano, K. Banno, T. Kaneda; “Determination of plasma Tenofovir concentrations using a conventional LC-MS method” Biological and Pharmaceutical Bulletin, 2007, 30(9), 1784-1786. [DOI: 10.1248/bpb.30.1784] |
[92] | M. Yadav, T. Mishra, P. Singhal, S. Goswami, P.S. Shrivastav; “Rapid and specific liquid chromatographic tandem mass spectrometric determination of Tenofovir in human plasma and its fragmentation study”, Journal of Chromatographic Science, 2009, 47(2), 140-148. [DOI: 10.1093/chromsci/47.2.140] |
[93] | S. Modi, B.D. Anderson; “Determination of Drug Release Kinetics from nanoparticles: overcoming pitfalls of the dynamic dialysis method”, Molecular Pharmaceutics, 2013, 10(8), 3076-3089. [DOI: 10.1021/mp400154a] |
[94] | B.U. Jaki, A. Bzhelyansky, G.F. Pauli; “Quantitative NMR (qNMR) forpharmaceutical analysis: The pioneering work of George Hanna at the US FDA”, Magnetic Resonance in Chemistry, 2021, (59), 7–15. [DOI: 10.1002/mrc.5099] |
[95] | J.N. Shoolery; “Some quantitative applications of 13C NMR spectroscopy”, Progress in NMR Spectroscopy. 1977, 11, 79-93. [DOI: 10.1016/0079-6565(77)80003-4] |
[96] | R. Greenhalgh, J.N. Shoolery; “Analysis of organo-phosphorus insecticide and formulations for contaminants by phosphorus-31 Fourier transform nuclear magnetic resonance spectrometry”, Analytical Chemistry, 1978, 50(14), 2039-2042. [DOI: 10.1021/ac50036a025] |
[97] | J.W. Turczan, T. Medwick; “Qualitative and Quantitative Analysis of Amygdalin Using NMR Spectroscopy”, Analytical Letters, 1977, 10(7-8), 581-590. [DOI: 10.1080/00032717708059224] |
[98] | J.L. Jungnickel, J.W. Forbes; “Quantitative Measurement of Hydrogen Types by Intergrated Nuclear Magnetic Resonance Intensities”, Analytical Chemistry, 1963, 35(8), 938-942. [DOI: 10.1021/ac60201a005] |
[99] | D.P. Hollis; “Quantitative analysis of Aspirin, Phenacetin, and Caffeine mixtures by nuclear magnetic resonance spectrometry”, Analytical Chemistry, 1963, 35(11), 1682-1684. [DOI: 10.1021/ac60204a043] |
[100] | M. Yang, J. Wang, L. Kong; “Quantitative analysis of four major diterpenoids in Andrographis paniculata by 1H NMR and its application for quality control of commercial preparation” Journal of Pharmaceutical and Biomedical Analysis, 2012, 70, 87-93. [DOI: 10.1016/j.jpba.2012.05.037] |
[101] | V. Pieri, A. Belancic, S. Morales, H. Stuppner; “Identification and quantification of major Steviol Glycosides in Stevia rebaudiana purified extracts by 1H NMR spectroscopy”, Journal of Agricultural and Food Chemistry, 2011, 59(9), 4378-4384. [DOI: 10.1021/jf104922q] |
[102] | J. Staneva, P. Denkova, M. Todorova, L. Evstatieva; “Quantitative analysis of sesquiterpene lactones in extract of Arnica montana L. by 1H NMR spectroscopy”, Journal of Pharmaceutical and Biomedical Analysis, 2011, 54(1), 94-99. [DOI: 10.1016/j.jpba.2010.08.018] |
[103] | G.M. Pinheiro, E.A. Basso, B.C. Fiorin, F. Cendes, R. Rittner, A.N. Oliveira, N.F. Hoehr; “A fast 1H NMR spectroscopy procedure for quantitative determination of N-acetylaspartate in urine samples”, Clinica Chimica Acta, 2009, 404(2), 166-168. [DOI: 10.1016/j.cca.2009.03.008] |
[104] | S.K. Bharti, R. Roy; “Quantitative 1H NMR spectroscopy”, Trends in Analytical Chemistry, 2012, (35), 5-26. [DOI: 10.1016/j.trac.2012.02.007] |
[105] | Good Laboratory Practice regulations 40 CFR Part 160 established by the Federal Insecticide, Fungicide and Rodenticide Act, and 21 CFR Part 58 established by the Federal Food, Drug, and Cosmetic Act, and the Organization for Economic Cooperation and Development Principles of Good Laboratory Practice as outlined in OECD/GD(92)32, Code of Federal Regulations, revised: 1997, Title 40, Volume 14, Parts 150 to 189, Page 125-137, CITE: 40CFR160. |
[106] | G.F. Pauli, T. Godecke, B.U. Jaki, D.C. Lankin; “Quantitative 1H NMR. Development and potential of an analytical method: an update”, Journal of Natural Products, 2012, 75(4), 834-851. [DOI: 10.1021/np200993k] |
[107] | F. Malz, H. Jancke; “Validation of quantitative NMR”, Journal of Pharmaceutical and Biomedical Analysis, 2005, 38(5), 813-823. [DOI: 10.1016/j.jpba.2005.01.043] |
[108] | G. Maniara, K. Rajamoorthi, S. Rajan, G.W. Stockton; “Method performance and validation for quantitative analysis by 1H and 31P NMR spectroscopy: Applications to analytical standards and agricultural chemicals”, Analytical Chemistry, 1998, 70(23), 4921-4928. [DOI: 10.1021/ac980573i] |
[109] | The United States Pharmacopoeia, USP XXII; United States Pharmacopoeia Convention, Inc.: Rockville, MD, 1992, Suppl. 7, 3140. |
[110] | British Pharmacopoeia, Medicines and Healthcare Products Regulatory Agency, Her Majesty’s Stationery Office; London, 1988; Vol. II. |
[111] | T. Beyer, B. Diehl, U. Holzgrabe; “Quantitative NMR spectroscopy of biologically active substances and excipients”, Bioanalytical Review, 2010, (2), 1-22. [DOI: 10.1007/s12566-010-0016-8] |
[112] | M. Malet-Martinoa, U. Holzgrabe; “NMR techniques in biomedical and pharmaceutical analysis”, Journal of Pharmaceutical and Biomedical Analysis, 2011, (55), 1-15. [DOI: 10.1016/j.jpba.2010.12.023] |
[113] | U. Holzgrabe ∗, R. Deubner, C. Schollmayer, B. Waibel; “Quantitative NMR spectroscopy-Applications in drug analysis”, Journal of Pharmaceutical and Biomedical Analysis, 2005, (38), 806-812. [DOI: 10.1016/j.jpba.2005.01.050] |
[114] | U. Holzgrabe; “Quantitative NMR spectroscopy in pharmaceutical applications”, Progress in Nuclear Magnetic Resonance Spectroscopy, 2010, 57, 229-240. [DOI: 10.1016/j.pnmrs.2010.05.001] |
[115] | M. Otsuka, T. Matsumoto, N. Kaneniwa; “Effects of the mechanical energy of multi-tableting compression on the polymorphic transformations of chlorpropamide”, Journal of Pharmacy and Pharmacology, 1989, 41(10), 665-669. [DOI: 10.1111/j.2042-7158.1989.tb06337.x] |
[116] | K.A. Connors, G.L. Amidon, V.J. Stella; “Chemical Stability of Pharmaceuticals: A Handbook for Pharmacist” 2nd edition, John Wiley & Sons, New York, 1986. (ISBN: 978-0-471-87955-8) |
[117] | R.T. Berendt, D.M. Sperger, P.K. Isbester, E.J. Munson; “Solid-state NMR spectroscopy in pharmaceutical research and analysis”, Trends in Analytical Chemistry, 2006, 25(10), 977-984. [DOI: 10.1016/j.trac.2006.07.006] |
[118] | P.A. Tishmack, D.E. Bugay, S.R. Byrn; “Solid-State Nuclear Magnetic Resonance Spectroscopy-Pharmaceutical Applications”, Journal of Pharmaceutical Sciences, 2003, 92(3), 441-474. [DOI: 10.1002/jps.10307] |
[119] | C. Zhang, T. Zhang, N.A. Oyler, B.-B.C. Youan; “Direct and real-time quantification of Tenofovir release from pH-sensitive microparticles into simulated biological fluids using 1H-NMR”, Journal of Pharmaceutical Sciences, 2014, 13(4), 1170-1177. [DOI: 10.1002/jps.23886] |
[120] | F.S. Coulibaly, M.J. Ezoulin, S.S. Purohit, N.J. Ayon, N.A. Oyler, B-B.C. Youan; “Layer by layer engineered microbicide drug delivery system targeting HIV-1 gp120: physicochemical and biological properties”, Molecular Pharmaceutics, 2017, 14(10), 3512-3527. [DOI: 10.1021/acs.molpharmaceut.7b00555] |
[121] | V. Agrahari, J. Meng, S.S. Purohit, N.A. Oyler, B-B.C. Youan; “Real-Time analysis of Tenofovir release kinetics using quantitative phosphorus (31P) nuclear magnetic resonance spectroscopy”, Journal of Pharmaceutical Sciences, 2017, 106(10), 3005-3015. [DOI: 10.1016/j.xphs.2017.03.043] |
[122] | J. Meng, V. Agrahari, S.S. Purohit, T. Zhang, M.J. Ezoulin, A. Molteni, D. Dim, N.A. Oyler, B-B.C. Youan; “Spray dried thiolated chitosan coated sodium alginate multilayer microparticles for vaginal HIV microbicide delivery”, The AAPS Journal, 2017, 19(3), 692-702. [DOI: 10.1208/s12248-016-0007-y] |
[123] | J. Meng, V. Agrahari, M.J. Ezoulin, C. Zhang, S.S. Purohit, A. Molteni, D. Dim, N.A. Oyler, B.-B.C. Youan; “Tenofovir containing thiolated chitosan core/shell nanofibers: in vitro and in vivo evaluations”, Molecular Pharmaceutics, 2016, 13(12), 4129-4140. [DOI: 10.1021/acs.molpharmaceut.6b00739] |
[124] | Harmonization ICo. Geneva, Switzerland: 2005. |
[125] | F.S. Coulibaly, A.S. Alnafisah, N.A. Oyler, B.-B.C. Youan; “Direct and real-time quantification of Bortezomib release from alginate microparticles using boron (11B) nuclear magnetic resonance spectroscopy”, Molecular Pharmaceutics, 2019, 16(3), 967-977. [DOI: 10.1021/acs.molpharmaceut.8b00873] |
[126] | A.O. Mattes, D. Russell, E. Tishchenko, Y. Liu, R.H. Cichewicz, S.J. Robinson; “Application of 19F quantitative NMR to pharmaceutical analysis”, Concepts in Magnetic Resonance, Part A, 2018, 45A(5), 1-8. [DOI: 10.1002/cmr.a.21422] |
[127] | C. Simmler, J.G. Napolitano, J.B. McAlpine, S.-N. Chen, G.F. Pauli; “Universal Quantitative NMR Analysis of Complex Natural Samples”, Current Opinion in Biotechnology, 2014, 51-59. [DOI: 10.1016/j.copbio.2013.08.004] |